XFOR Aug 2024 0.500 call
| Previous close | 0.6000 |
| Open | 0.5000 |
| Bid | 0.5000 |
| Ask | 0.5500 |
| Strike | 0.50 |
| Expiry date | 2024-08-16 |
| Day's range | 0.4800 - 0.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 413 |
GlobeNewswireX4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming H.C. Wainwright 2nd Annual BioConnect Investor Conference, taking place on May 20th, 2024, at the Nasdaq Stock Exchange in New York City. H.C. Wainwright 2nd Annual BioConnect Investor ConferenceDate: Monday, May 20, 2024Time: 2:00 PM ETFormat: Fireside ChatWebcast
- GlobeNewswire
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor) XOLREMDI, the first drug indicated in patients with WHIM syndrome, received U.S. FDA approval in April 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it has completed the sale of its Rare Pediatric Disease Pr
Insider MonkeyX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript May 7, 2024 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.25884 EPS, expectations were $-0.17. X4 Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: [Indiscernible] X4 […]
